Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

NCT02228096 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia
Relapsed B-cell Acute Lymphoblastic Leukemia
Refractory B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: CTL019 T-cells

Sponsor

Novartis Pharmaceuticals